Profile data is unavailable for this security.
About the company
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.
- Revenue in USD (TTM)12.92m
- Net income in USD-54.39m
- Incorporated2017
- Employees69.00
- LocationScholar Rock Holding Corp620 Memorial Dr Fl 2CAMBRIDGE 02139-4815United StatesUSA
- Phone+1 (857) 259-3860
- Fax+1 (302) 655-5049
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | -100.00bn | -100.00bn | 468.45m | 29.00 | -- | 2.85 | -- | -- | -- | -- | -- | 6.48 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Atreca Inc | 0.00 | -59.36m | 471.15m | 102.00 | -- | 2.92 | -- | -- | -2.19 | -2.19 | 0.00 | 7.33 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -37.83 | -- | -- | -- |
| BioDelivery Sciences International, Inc. | 97.78m | -21.62m | 472.04m | 164.00 | -- | 6.94 | -- | 4.83 | -0.282 | -0.282 | 1.18 | 0.7562 | 0.6764 | 2.27 | 4.25 | 596,225.60 | -14.95 | -46.36 | -19.77 | -67.31 | 81.24 | 72.96 | -22.11 | -85.14 | 2.02 | -0.0707 | 0.4629 | -- | -10.24 | 37.41 | -977.33 | -- | 7.81 | -- |
| CytoDyn Inc | 0.00 | -58.49m | 473.83m | 10.00 | -- | -- | -- | -- | -0.1722 | -0.1722 | 0.00 | -0.0342 | 0.00 | -- | -- | 0.00 | -305.38 | -396.98 | -- | -- | -- | -- | -- | -- | -- | -7.28 | -- | -- | -- | -- | -12.04 | -- | 18.69 | -- |
| Calithera Biosciences Inc | 0.00 | -87.63m | 477.52m | 79.00 | -- | 3.35 | -- | -- | -2.08 | -2.08 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -59.61 | -33.84 | -66.17 | -38.25 | -- | -- | -- | -362.62 | -- | -- | 0.00 | -- | -14.26 | -- | -96.32 | -- | 5.47 | -- |
| Xenon Pharmaceuticals Inc | 3.50m | -37.26m | 479.50m | 89.00 | -- | 5.95 | -- | 137.00 | -1.45 | -1.45 | 0.1364 | 2.88 | 0.0305 | -- | 17.99 | 39,325.84 | -33.81 | -25.73 | -36.37 | -28.64 | 100.00 | -- | -1,107.91 | -197.42 | -- | -- | 0.1712 | -- | -100.00 | -- | -2.97 | -- | 26.58 | -- |
| Morphic Holding Inc | 20.67m | -28.84m | 480.12m | 65.00 | -- | 2.97 | -- | 23.23 | -0.9704 | -0.9704 | 0.696 | 5.31 | -- | -- | -- | 558,594.60 | -- | -- | -- | -- | -- | -- | -139.54 | -- | -- | -- | 0.00 | -- | -- | -- | -40.85 | -- | -- | -- |
| Scholar Rock Holding Corp | 12.92m | -54.39m | 484.65m | 69.00 | -- | 3.98 | -- | 37.51 | -2.41 | -2.41 | 0.536 | 4.10 | 0.0868 | -- | -- | 198,753.80 | -36.56 | -- | -41.96 | -- | -- | -- | -421.03 | -- | -- | -- | 0.00 | -- | -- | -- | -97.34 | -- | -- | -- |
| Prothena Corporation PLC | 814.00k | -77.68m | 486.34m | 59.00 | -- | 1.78 | -- | 597.47 | -1.95 | -1.95 | 0.0204 | 6.84 | 0.0018 | -- | -- | -- | -16.92 | -28.50 | -17.55 | -30.30 | -- | -- | -9,542.63 | -1,964.57 | -- | -- | -- | -- | -14.76 | -56.26 | 50.09 | -- | -- | -- |
| Puma Biotechnology Inc | 272.24m | -75.60m | 488.96m | 272.00 | -- | -- | -- | 1.80 | -1.95 | -1.95 | 7.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 86.49 | -- | -27.77 | -180.85 | -- | -3.20 | -- | -- | 8.49 | -- | 33.44 | -- | -- | -- |
| Beyondspring Inc | 0.00 | -38.13m | 490.29m | 52.00 | -- | 22.31 | -- | -- | -1.62 | -1.62 | 0.00 | 0.7886 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -159.57 | 0.0591 | -- | -- | -- | 40.21 | -- | -- | -- |
| Neoleukin Therapeutics Inc | 0.00 | -66.23m | 491.09m | 8.00 | -- | 4.25 | -- | -- | -2.56 | -2.56 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -84.04 | -35.82 | -91.80 | -38.65 | -- | -- | -- | -667.83 | -- | -- | 0.0032 | -- | -- | -- | 39.82 | -- | 34.82 | -- |
| Viking Therapeutics Inc | 0.00 | -23.57m | 493.56m | 15.00 | -- | 1.74 | -- | -- | -0.3282 | -0.3282 | 0.00 | 3.92 | 0.00 | -- | -- | 0.00 | -7.90 | -49.74 | -8.04 | -62.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.22 | -- | -- | -- |
| Magenta Therapeutics Inc | 0.00 | -70.21m | 495.56m | 72.00 | -- | 3.06 | -- | -- | -1.97 | -1.97 | 0.00 | 4.15 | 0.00 | -- | -- | 0.00 | -40.12 | -- | -42.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.23 | -- | -- | -- |
| 89bio Inc | 0.00 | -42.78m | 499.85m | 17.00 | -- | -- | -- | -- | -3.55 | -3.55 | 0.00 | -0.3502 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Merus NV | 32.41m | -29.38m | 501.31m | 98.00 | -- | 5.32 | -- | 15.47 | -1.26 | -1.26 | 1.39 | 3.26 | 0.1441 | -- | 12.12 | 330,719.90 | -13.06 | -41.80 | -15.62 | -49.24 | -- | -- | -90.64 | -299.35 | -- | -- | 0.0208 | -- | 43.50 | 123.97 | 62.53 | -- | 79.62 | -- |
Data as of Feb 25 2020. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD
56.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2019 | 4.45m | 15.00% |
| Redmile Group LLCas of 31 Dec 2019 | 2.94m | 9.91% |
| Bellevue Asset Management AGas of 31 Dec 2019 | 2.63m | 8.88% |
| Invus Public Equities Advisors LLCas of 31 Dec 2019 | 2.55m | 8.58% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2019 | 1.26m | 4.24% |
| BlackRock Fund Advisorsas of 31 Dec 2019 | 1.17m | 3.95% |
| The Vanguard Group, Inc.as of 31 Dec 2019 | 905.65k | 3.05% |
| SSgA Funds Management, Inc.as of 31 Dec 2019 | 354.48k | 1.19% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 255.00k | 0.86% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2019 | 247.68k | 0.84% |
More ▼
Data from 31 Dec 2018 - 31 Dec 2019Source: FactSet Research Systems Inc.
